1. Home
  2. ACRS vs ATLO Comparison

ACRS vs ATLO Comparison

Compare ACRS & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • ATLO
  • Stock Information
  • Founded
  • ACRS 2012
  • ATLO 1903
  • Country
  • ACRS United States
  • ATLO United States
  • Employees
  • ACRS N/A
  • ATLO N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • ACRS Health Care
  • ATLO Finance
  • Exchange
  • ACRS Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • ACRS 198.2M
  • ATLO 180.3M
  • IPO Year
  • ACRS 2015
  • ATLO N/A
  • Fundamental
  • Price
  • ACRS $2.31
  • ATLO $20.76
  • Analyst Decision
  • ACRS Strong Buy
  • ATLO
  • Analyst Count
  • ACRS 9
  • ATLO 0
  • Target Price
  • ACRS $9.25
  • ATLO N/A
  • AVG Volume (30 Days)
  • ACRS 1.3M
  • ATLO 23.2K
  • Earning Date
  • ACRS 11-06-2025
  • ATLO 10-17-2025
  • Dividend Yield
  • ACRS N/A
  • ATLO 3.85%
  • EPS Growth
  • ACRS N/A
  • ATLO 82.22
  • EPS
  • ACRS N/A
  • ATLO 1.79
  • Revenue
  • ACRS $16,789,000.00
  • ATLO $60,568,000.00
  • Revenue This Year
  • ACRS N/A
  • ATLO N/A
  • Revenue Next Year
  • ACRS N/A
  • ATLO N/A
  • P/E Ratio
  • ACRS N/A
  • ATLO $11.94
  • Revenue Growth
  • ACRS N/A
  • ATLO 18.60
  • 52 Week Low
  • ACRS $1.05
  • ATLO $15.75
  • 52 Week High
  • ACRS $5.17
  • ATLO $21.48
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 62.06
  • ATLO 55.69
  • Support Level
  • ACRS $2.24
  • ATLO $19.56
  • Resistance Level
  • ACRS $2.47
  • ATLO $21.00
  • Average True Range (ATR)
  • ACRS 0.19
  • ATLO 0.46
  • MACD
  • ACRS 0.03
  • ATLO 0.10
  • Stochastic Oscillator
  • ACRS 77.92
  • ATLO 63.16

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.

Share on Social Networks: